PhD
AMU, IPC, CRCM
We have developed a library of human tumors xenografted on immunodepressed mice
Pancreatic cancer is one of the most difficult solid tumors to treat as it progresses silently without any particular warning signs. Its capacity to spread malignant cells to other organs (liver, lymph nodes, peritonium…) often catches the medical profession unaware and prevents it from making an early diagnosis. One of the directions for research in my laboratory in the framework of the “PacaOmics” clinical trial program at the IPC and the APHM consists in characterizing new prognostic biomarkers and predictive of the therapeutic response of pancreatic tumors in order to facilitate the management of patients.
In the era of personalized medicine, it has become crucial to be able to provide surgeons, oncologists, gastroenterologists and radiologists with an accurate picture of the level of heterogeneity of the molecular scale of their patients’ tumors. We have therefore developed a library of human tumors xenografted on immunodepressed mice that perfectly reproduce the characteristics of primary tumors in patients from whom they have been extracted. These mice models today allow us to perform large scale analyses of DNA and gene expression, metabolism, proteins secreted by these tumors, as well as their susceptibility profile to a broad range of drugs
The success of this collection of pancreatic xenografts is the fruit of great interdisciplinarity and illustrates more broadly the relevance of translational research programs and biomedicine supported by Marseille Immunopole.
#rechercheMI both accelerates research and development in immuno-oncology and offers cancer patients more options in terms of diagnostics and treatments, as well as more innovative clinical trials.
Fabrice BARLESI
Université Paris-Saclay, Gustave Roussy, The Pioneer Project
This is the DNA of the cluster to feed local excellence, including, of course, fundamental and applied immunology, and to support the emergence of sector initiatives with strong potential.
Émilie ROYERE
Eurobiomed
Diagnostic in immuno-oncology is an innovative field combining the latest discoveries in immunology and new imaging technologies, such as digital pathology.
Fabienne HERMITTE
Veracyte
Marseille Immunopole is born from the will of all partners to do even better and progress faster, and thus allow patients always to keep one step ahead of the disease.
Éric VIVIER
AMU, AP-HM, CIML, INNATE PHARMA